DexCom’s Earnings Are Growing Faster Than Its Stock Price

DexCom, Inc. (DXCM) shares have pushed toward the upper end of their two-year range, trading at $83.45 versus a two-year high of $89.07 and low of $55.00. This DexCom stock analysis looks at whether the continuous glucose monitoring leader’s fundamentals justify the move, or whether the market has gotten ahead of itself.

What Is Happening With the Stock Price

At $83.45, DXCM sits toward the upper end of its two-year trading band, well above the $55.00 low and closing in on the $89.07 high. The move reflects renewed investor enthusiasm for the stock after a period of underperformance, with the market rewarding accelerating profitability alongside continued top-line growth. At a $31.49 billion market cap, DexCom remains a mid-cap name whose valuation now embeds real growth expectations.

Quality: Is This a Financially Sound Business?

The Quality picture here is strong. DexCom converts sales efficiently, with a 62.5% gross margin and a 24.3% operating margin feeding through to a 20.1% net margin. Profitability is also well-supported by cash generation: trailing twelve-month free cash flow of $1.0 billion against $5.0 billion in revenue points to real cash conversion, not just accounting profit. Capital efficiency is a standout, with return on equity of 38.5% and return on assets of 10.3%. The balance sheet is sound, with a current ratio of 1.73, a quick ratio of 1.37, and modest leverage at a 0.53 debt-to-equity ratio. Taken together, this DexCom stock analysis finds a business with genuine financial durability, not just narrative momentum.

Growth: Does This Company Have Real Upside?

Growth is real but decelerating from its historical pace. Revenue has compounded at a 17.0% five-year CAGR, while the trailing-twelve-month growth rate of 13.1% suggests the business is maturing off its earlier hyper-growth phase. Earnings, however, are growing much faster than revenue, up 43.6% on a trailing-twelve-month basis, evidence of margin expansion doing real work alongside unit growth. The EV/Revenue multiple of 6.23 reflects a market willing to pay up for that combination of durable growth and improving profitability, though it also leaves less room for error if growth slows further.

Opportunity: Is Now a Good Time to Enter?

Valuation is the weak link in the setup. A P/E ratio of 32.98, an EV/EBITDA of 22.05, and a price-to-book of 12.01 are all elevated, and an FCF yield of just 3.2% is modest for a business now priced toward the top of its two-year range. None of this makes DexCom expensive relative to its own growth and quality profile, but it does mean today’s price already assumes a fair amount of continued execution, leaving a thinner margin of safety for new buyers than existed lower in the range.

DexCom Stock Analysis: The Bottom Line

DexCom pairs genuinely strong quality (a 88/100 Quality score) with still-solid, if decelerating, growth (63/100) – but Opportunity lags at just 34/100 given how much of that quality is already priced in. StreetBriefs’ quantitative scoring model still nets this out to an overall Buy signal (Recommendation Score: 62/100), a data-driven signal for further research, not a personalized recommendation to transact. Investors weighing this name might consider that the bull case rests on continued margin expansion and steady CGM adoption, while the key risk is that with the stock near two-year highs, any growth disappointment or competitive pressure in glucose monitoring could compress the current premium multiple quickly. As always, this reflects Yahoo Finance data as of August 03, 2026, and is informational only – not personalized investment advice; do your own due diligence or consult a licensed advisor.